$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000139047822000012 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$1.000M	$0.00	$5.700M
YoY Change	-82.46%	-100.0%
Cost Of Revenue	$100.0K	$0.00	$100.0K
YoY Change	0.0%
Gross Profit	$900.0K	$0.00	$5.600M
YoY Change	-83.93%
Gross Profit Margin	90.0%		98.25%
Selling, General & Admin	$3.024M	$2.526M	$3.561M
YoY Change	-15.08%	-23.22%	61.86%
% of Gross Profit	336.0%		63.59%
Research & Development	$4.611M	$3.393M	$4.284M
YoY Change	7.63%	22.49%	129.83%
% of Gross Profit	512.33%		76.5%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$7.635M	$5.919M	$7.845M
YoY Change	-2.68%	-2.33%	93.04%
Operating Profit	-$16.74M	-$5.919M	-$2.245M
YoY Change	645.43%		-44.76%
Interest Expense	$2.000K	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	$4.784M	-$160.0K
YoY Change	-93.13%	1012.56%	60.0%
Pretax Income	-$16.74M	-$6.835M	-$2.400M
YoY Change	597.67%	83.24%	-42.03%
Income Tax		-$237.0K
% Of Pretax Income
Net Earnings	-$16.70M	-$6.598M	-$2.403M
YoY Change	594.96%	77.37%	-42.0%
Net Earnings / Revenue	-1670.0%		-42.16%
Basic Earnings Per Share	-$1.05		-$0.16
Diluted Earnings Per Share	-$1.05	-$415.2K	-$0.16
COMMON SHARES
Basic Shares Outstanding	15.90M shares	15.89M shares	14.88M shares
Diluted Shares Outstanding	15.90M shares		14.88M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.25M	$21.36M	$28.00M
YoY Change	-49.1%	-39.5%	317.91%
Cash & Equivalents	$14.30M	$21.36M	$28.00M
Short-Term Investments
Other Short-Term Assets	$2.587M	$1.689M	$3.100M
YoY Change	-16.55%	237.8%	47.62%
Inventory
Prepaid Expenses
Receivables	$1.000M	$0.00	$300.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.84M	$23.04M	$31.43M
YoY Change	-43.24%	-37.59%	257.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.127M	$723.0K	$900.0K
YoY Change	25.22%	-19.67%	800.0%
Goodwill	$1.914M	$1.914M	$1.914M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$554.0K	$594.0K	$700.0K
YoY Change	-20.86%	-1.0%	40.0%
Total Long-Term Assets	$3.595M	$3.231M	$9.144M
YoY Change	-60.68%	-64.59%	11.02%
TOTAL ASSETS
Total Short-Term Assets	$17.84M	$23.04M	$31.43M
Total Long-Term Assets	$3.595M	$3.231M	$9.144M
Total Assets	$21.43M	$26.28M	$40.58M
YoY Change	-47.17%	-42.94%	138.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.842M	$2.144M	$2.350M
YoY Change	20.94%	-53.96%	-10.44%
Accrued Expenses	$3.012M	$2.640M	$2.547M
YoY Change	18.26%	38.0%	186.82%
Deferred Revenue		$0.00	$900.0K
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.68M	$4.982M	$5.971M
YoY Change	78.85%	-59.61%	64.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.730M	$946.0K	$5.600M
YoY Change	20.18%	-82.8%	9.8%
Total Long-Term Liabilities	$6.730M	$946.0K	$5.600M
YoY Change	20.18%	-82.8%	9.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.68M	$4.982M	$5.971M
Total Long-Term Liabilities	$6.730M	$946.0K	$5.600M
Total Liabilities	$17.41M	$5.928M	$11.83M
YoY Change	47.12%	-67.23%	32.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$155.3M	-$138.6M	-$120.3M
YoY Change	29.09%	17.56%	14.25%
Common Stock	$159.4M	$159.0M	$149.0M
YoY Change	6.93%	8.97%	31.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.025M	$20.35M	$28.74M
YoY Change
Total Liabilities & Shareholders Equity	$21.43M	$26.28M	$40.58M
YoY Change	-47.17%	-42.94%	138.31%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$16.70M	-$6.598M	-$2.403M
YoY Change	594.96%	77.37%	-42.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$7.200M	-$4.976M	-$10.27M
YoY Change	-29.89%	-245.5%	50.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$47.00K	50.00K	$3.000M
YoY Change	-98.43%	-99.79%	-52.38%
NET CHANGE
Cash From Operating Activities	-$7.200M	-4.976M	-$10.27M
Cash From Investing Activities
Cash From Financing Activities	$47.00K	50.00K	$3.000M
Net Change In Cash	-$7.103M	-4.926M	-$7.269M
YoY Change	-2.28%	-118.18%	1268.93%
FREE CASH FLOW
Cash From Operating Activities	-$7.200M	-$4.976M	-$10.27M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-33958
CY2022Q1	dei	Entity File Number EntityFileNumber	001-33958
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8099512
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Times Square, Suite 2503,
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2022Q1	dei	City Area Code CityAreaCode	(646)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	200-5278
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	SLS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20535629	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14252000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21355000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2487000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1589000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	17839000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	23044000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1127000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	723000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	1914000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	1914000	USD
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	554000	USD
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	594000	USD
CY2022Q1	us-gaap	Assets Assets	21434000	USD
CY2021Q4	us-gaap	Assets Assets	26275000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2842000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2144000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3012000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2640000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	325000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198000	USD
CY2022Q1	sls	Acquired In Process Research And Development Payable Current AcquiredInProcessResearchAndDevelopmentPayableCurrent	4500000	USD
CY2021Q4	sls	Acquired In Process Research And Development Payable Current AcquiredInProcessResearchAndDevelopmentPayableCurrent	0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10679000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4982000	USD
CY2022Q1	sls	Acquired In Process Research And Development Payable Non Current AcquiredInProcessResearchAndDevelopmentPayableNonCurrent	5500000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3024000	USD
CY2021Q4	sls	Acquired In Process Research And Development Payable Non Current AcquiredInProcessResearchAndDevelopmentPayableNonCurrent	0	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	883000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	610000	USD
CY2022Q1	sls	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	51000	USD
CY2021Q4	sls	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	40000	USD
CY2022Q1	sls	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	296000	USD
CY2021Q4	sls	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	296000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	17409000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	5928000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15905999	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15905999	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15895637	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15895637	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	159370000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158948000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155347000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138603000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4025000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20347000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21434000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26275000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1000000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5700000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4611000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4284000	USD
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	10000000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3561000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	17735000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	7945000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16735000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2245000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	31000	USD
CY2022Q1	sls	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	0	USD
CY2021Q1	sls	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-129000	USD
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2000	USD
CY2021Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2000	USD
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-9000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-158000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16744000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2403000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15897479	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15897479	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14877317	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14877317	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20347000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	47000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	375000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16744000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4025000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27961000	USD
CY2021Q1	sls	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	3000000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	184000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2403000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	28742000	USD
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	10000000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	375000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	184000	USD
CY2022Q1	sls	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	45000	USD
CY2021Q1	sls	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	0	USD
CY2022Q1	sls	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-11000	USD
CY2021Q1	sls	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-31000	USD
CY2022Q1	sls	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	0	USD
CY2021Q1	sls	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-129000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	564000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1000000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	606000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2683000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	667000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-897000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	151000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	634000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-49000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		USD
CY2022Q1	sls	Increase Decrease In Contract With Customer Liability Net IncreaseDecreaseInContractWithCustomerLiabilityNet	0	USD
CY2021Q1	sls	Increase Decrease In Contract With Customer Liability Net IncreaseDecreaseInContractWithCustomerLiabilityNet	-4700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7150000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10269000	USD
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	47000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7269000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21455000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35402000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14352000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7103000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28133000	USD
CY2022Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2000	USD
CY2021Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	USD
CY2022Q1	sls	Acquired In Process Research And Development Payable AcquiredInProcessResearchAndDevelopmentPayable	10000000	USD
CY2021Q1	sls	Acquired In Process Research And Development Payable AcquiredInProcessResearchAndDevelopmentPayable	0	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	449000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	sls	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	252000	USD
CY2021Q1	sls	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2022Q1	sls	Research And Development Arrangement Potential Milestone Payments To Be Received ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived	191500000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155300000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16700000	USD
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	10000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7200000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14300000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000	USD
CY2022Q1	sls	Research And Development Arrangement Milestone Payment Receivable ResearchAndDevelopmentArrangementMilestonePaymentReceivable	1000000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1821000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1257000	shares
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1262000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	217000	USD
CY2022Q1	sls	Prepaid Research And Development PrepaidResearchAndDevelopment	811000	USD
CY2021Q4	sls	Prepaid Research And Development PrepaidResearchAndDevelopment	1309000	USD
CY2022Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	252000	USD
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2022Q1	sls	Prepaid Professional Services PrepaidProfessionalServices	151000	USD
CY2021Q4	sls	Prepaid Professional Services PrepaidProfessionalServices	36000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	11000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	27000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2487000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1589000	USD
CY2022Q1	sls	Contract Research Payable ContractResearchPayable	2049000	USD
CY2021Q4	sls	Contract Research Payable ContractResearchPayable	1325000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	446000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	989000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	261000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	165000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	256000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	161000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3012000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2640000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	378000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	518000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	533000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1429000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	221000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1208000	USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	518000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1006000	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2797000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	519000	shares
CY2022Q1	sls	Classof Warrantor Right Canceled Or Expired ClassofWarrantorRightCanceledOrExpired	1000	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	518000	shares
CY2021Q4	sls	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	40000	USD
CY2022Q1	sls	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	11000	USD
CY2022Q1	sls	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	51000	USD
CY2020Q4	sls	Research And Development Arrangement Cash Payment Received ResearchAndDevelopmentArrangementCashPaymentReceived	7500000	USD
CY2020Q4	sls	Research And Development Arrangement Potential Milestone Payments To Be Received Maximum ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum	194500000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9500000	USD
CY2020Q4	sls	Research And Development Arrangement Cash Payment Received ResearchAndDevelopmentArrangementCashPaymentReceived	7500000	USD
CY2020Q4	sls	Research And Development Arrangement Milestones Probable Of Being Achieved ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved	2000000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9500000	USD
CY2021	sls	Research And Development Arrangement Potential Milestone Payments To Be Received ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived	192500000	USD
CY2022Q1	sls	Research And Development Arrangement Potential Milestone Payments To Be Received ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived	191500000	USD
CY2022Q1	sls	Contract With Customer Liability New Contract Revenue Recognized ContractWithCustomerLiabilityNewContractRevenueRecognized	1000000	USD
CY2021Q1	sls	Contract With Customer Liability New Contract Revenue Recognized ContractWithCustomerLiabilityNewContractRevenueRecognized	5700000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	375000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	184000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	534000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.09
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	681000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	472000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.31
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1006000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.85
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M20D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1540000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	214000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.43
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M7D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	500000	USD
CY2022Q1	sls	Closing Price Of Common Stock ClosingPriceOfCommonStock	6.68
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0179
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0103
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3043
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2120
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M1D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.79
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.98
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4000000	USD
CY2022Q1	sls	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P3Y1M13D

Files In Submission

Name	View Source	Status
0001390478-22-000012-index-headers.html	Edgar Link	pending
0001390478-22-000012-index.html	Edgar Link	pending
0001390478-22-000012.txt	Edgar Link	pending
0001390478-22-000012-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sls-20220331.htm	Edgar Link	pending
sls-20220331.xsd	Edgar Link	pending
sls-20220331ex101.htm	Edgar Link	pending
sls-20220331ex311.htm	Edgar Link	pending
sls-20220331ex312.htm	Edgar Link	pending
sls-20220331ex321.htm	Edgar Link	pending
sls-20220331_cal.xml	Edgar Link	unprocessable
sls-20220331_def.xml	Edgar Link	unprocessable
sls-20220331_g1.jpg	Edgar Link	pending
sls-20220331_htm.xml	Edgar Link	completed
sls-20220331_lab.xml	Edgar Link	unprocessable
sls-20220331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2022 Q1 Form 10-Q Financial Statement

#000139047822000012 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2022 Q1 Form 10-Q Financial Statement

#000139047822000012 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls